Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!
Note: You can unsubscribe from the alerts at any time.
Advertising

Johnson & Johnson pays $300m to develop cusatuzumab

pharmatimesDecember 06, 2018

Tag: Johnson & Johnson , AML , cusatuzumab , experimental antibody

PharmaSources Customer Service